The reporter learned that Pfizer's innovative drug for treating prostate cancer, Terzena& reg; （TALZENNA®， The generic name: Terazopanib Tosylate Capsules was approved by the National Medical Products Administration (NMPA) on October 29, 2024, in combination with enzalutamide for the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult patients with HRR gene mutations. As the only PARP inhibitor approved for mCRPC treatment of HRR gene mutations in China, Taizena& reg; It will help China achieve breakthroughs in precision diagnosis and treatment of prostate cancer, benefiting Chinese prostate cancer patients. (21st Century Business Herald)